• Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies
• The facility will feature state-of-the-art automation and sustainability solutions, reflecting a commitment to excellence in this industry 
• By 2026, the site ramp-up will be supported by a dedicated team of approximately 40 members, scaling up to 100 as production begins

Lisbon, March 18, 2025 – The first construction phase of the Hovione Tejo Campus in Seixal has entered its final stage, with commissioning set for mid-2027. Spanning 42 hectares to support future expansions, the site will initially feature two production buildings, one for particle engineering technologies and one for final dosage forms. Facilities will be equipped with cutting-edge automation. With an initial investment of around €200 million, the project will create around one hundred highly skilled jobs, enabling Hovione to expand its industrial capacity and reinforce its global position.

With the opening of this new Campus, Hovione will operate five manufacturing sites across three continents: two in Portugal (Loures and Seixal), and one each in Ireland (Cork), the United States (New Jersey), and Macau. 

“This new phase of Hovione Tejo´s construction is a major step in the company’s international expansion. By combining state-of-the-art scientific and engineering expertise and cutting-edge technology, this greenfield expansion will enable compliant and efficient manufacturing of complex new medicines for our customers. It will also create numerous direct and indirect qualified jobs, strengthening the pharmaceutical ecosystem in the beautiful region of Seixal. The products manufactured here will be exported worldwide, contributing to improving the health of millions of people”, said Dr. Jean-Luc Herbeaux, CEO of Hovione. 

The two initial production buildings will be complemented by supporting infrastructure such as laboratories, offices, cafeteria and other shared facilities. The new Campus will incorporate advanced sustainability and decarbonization solutions to minimize environmental impact and ensure energy efficiency. 

Operations will begin with 40 team members in 2026, increasing to 100 once production starts. “We have assembled a multidisciplinary team, drawing expertise from our entire organization, to design a Campus that sets new standards. It will provide an exceptional environment for our team members, suppliers and customers, conducive to the development of new solutions based on high yield collaborations”, added Dr. Jean-Luc Herbeaux.

About Hovione 

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.